Clinical data may validate a therapy, but it is the narrative around that data that determines whether the media, investors, and patients pay attention.

Biotech companies developing new therapies often focus on clinical data while overlooking the biotech media strategy and narrative needed to communicate their discoveries. In healthcare communications, scientific results alone rarely generate media coverage. Companies must build the story alongside the science to explain why new treatments matter. Biotech companies spend years developing a treatment, yet many only begin thinking about their story and biotech media strategy when it is time to issue a press release.

By then, the opportunity is often lost.

In healthcare media, data alone rarely drives coverage. Journalists need context, credibility, and a clear explanation of why the science matters. A clinical result may be scientifically impressive, but without a narrative that connects the evidence to patients, physicians, and healthcare systems, the story may never reach the public.

The companies that succeed understand something fundamental: the story must be built alongside the science.

In other words, they build the story as they create the treatment.

Why Data Alone Is Not Enough

Scientific data answers one important question: what happened in the trial.

But journalists are trying to answer a different question:

Why does this matter?

Healthcare reporters constantly evaluate new studies, therapies, and claims. They must determine quickly whether a development represents incremental progress or something that could change the treatment landscape.

If companies present only data, journalists are left to determine the significance on their own. Most do not have the time to reconstruct the broader context of the science.

The most effective healthcare communications teams make that context visible.

Global Storytelling Requires Local Understanding

While the core elements of a healthcare story are universal, the emphasis often differs across markets.

In the United States, healthcare journalism frequently follows the trajectory of innovation. Reporters may focus on breakthrough potential, early clinical signals, and the momentum of the biotech ecosystem.

European healthcare reporters, by contrast, often place greater emphasis on evidence, clinical significance, and the implications for healthcare systems.

Companies launching globally therefore need to do more than communicate the science. They must also understand how journalists in different regions evaluate the significance of new treatments.

Building a Biotech Media Strategy Alongside the Science

The narrative surrounding a therapy should not be created at the end of the process. It should be documented throughout the development journey.

The most effective biotech companies treat narrative development as a parallel process to scientific development.

As treatments move from discovery through clinical development, companies should capture the key elements that help journalists understand both the science and its implications.

These elements include:

1. The Medical Problem
What unmet need does the therapy address? How are patients currently treated, and where do existing options fall short?

2. The Origin of the Research
What insight or discovery sparked the work? Every scientific breakthrough has a beginning, and those moments help humanize complex science.

3. The Scientific Milestones
What discoveries moved the research forward? Journalists often need a timeline that explains how the science progressed.

4. Independent Credibility
Which clinicians, researchers, or experts can validate the significance of the work? Independent perspectives are essential in healthcare reporting.

5. The Patient Impact
How might this therapy change patients’ lives? What would success look like in real-world care?

6. The Evidence in Context
How does the therapy compare with current treatments? Is the result incremental or transformative?

When these elements are captured throughout development, companies are better prepared to communicate the significance of their work when key milestones occur.

Turning Science into Public Understanding

Scientific breakthroughs change medicine only when they are understood beyond the laboratory.

Healthcare journalism plays a critical role in translating complex discoveries into information that patients, clinicians, and policymakers can understand.

Companies that adopt a strong biotech media strategy early in the development process are far more likely to see their innovations reach global audiences.

A Practical Tool for Biotech Teams

For teams developing new therapies, I’ve created a simple Build-the-Story Checklist designed to help companies capture the narrative elements journalists need to understand the science.

In today’s competitive life sciences landscape, a thoughtful biotech media strategy can determine whether groundbreaking science gains global attention or remains unnoticed.

If you’re thinking about how to prepare for media engagement around a clinical milestone or launch, I’d be happy to talk through how to approach it. Even an early conversation can help clarify what a media readiness checklist should include for your organization.